Floatz logo

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

Cerebral Small Vessel Disease

First Affiliated Hospital of Chengdu Medical CollegeSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Cerebral Small Vessel Disease cohort.

Asset / SponsorPhaseRating
Plavix
First Affiliated Hospital of Chengdu Medical College
Phase 4BB
Acetylsalicylic Acid
First Affiliated Hospital of Chengdu Medical College
Phase 4BB
Dexborneol
Peking Union Medical College Hospital
Phase 3B

Same molecule, other indications

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril is also rated in:

cerebral infarctionDormant
BBB
Indicative ·
79 / 100
View asset →
transient ischemic attackDormant
BBB
Indicative ·
75 / 100
View asset →
ischemic strokeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →